Capitalizing on investors' interest in companies developing drugs for nonalcoholic steatohepatitis (NASH) as it awaits Phase III results for lead drug candidate elafibranor, Genfit SA went public in the US on March 26 at $20.32 per American depository share (ADS) and ended its first trading day up 9.1% at $22.17 on March 27.
Genfit Chief Operating Officer Dean Hum told Scrip that the main reason the French firm – which already trades on...






